Study details
Enrolling now
PTX-912 Clinical Trial
Proviva Therapeutics, Inc.
NCT IDNCT06190886ClinicalTrials.gov data as of Apr 2026
Phase
Phase 1
Target enrollment
26
Study length
about 2.1 years
Ages
18+
Locations
3 sites in CA, FL, NE
About this study
This trial is testing the safety and how well PTX-912 works in people with advanced or metastatic solid tumors. The goal is to determine a safe dose of PTX-912, understand its effects on the body (pharmacokinetics), and see if it has any anti-cancer activity.
Based on ClinicalTrials.gov records.
What participants do
- 1.Take PTX-912
PhasePhase 1
Primary goalDLTs (dose limiting toxicity)
Participation effort
Estimated from trial records. Details can vary by site.
Time + visits
Low15%
Logistics
Moderate50%
Logistics difficulty varies by site location and availability.
Trial highlights
Treatment details
Auto-extracted from trial records to preview treatments and outcomes.
Endpoints
Primary: DLTs (dose limiting toxicity)
Body systems
Oncology